Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Lung cancer has the lowest survival rate due to its late-stage diagnosis, poor prognosis, and intra-tumoral heterogeneity. These factors decrease the effectiveness of treatment. They release chemokines and cytokines from the tumor microenvironment (TME). To improve the effectiveness of treatment, re...

Full description

Bibliographic Details
Main Authors: Kangkan Sarma, Md Habban Akther, Irfan Ahmad, Obaid Afzal, Abdulmalik S. A. Altamimi, Manal A. Alossaimi, Mariusz Jaremko, Abdul-Hamid Emwas, Preety Gautam
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Molecules
Subjects:
TME
nanocarrier
lung cancer
vascular modification
PTT
ROS
Online Access:https://www.mdpi.com/1420-3049/29/5/1076

Internet

https://www.mdpi.com/1420-3049/29/5/1076

Similar Items